WO2023240146A3 - COMPOSITIONS INCLUDING CANDIDA DUBLINIENSIS AND ALKALINIZED FUNGAL β-GLUCANS FOR PROTECTION AGAINST INFECTION-INDUCED SEPSIS - Google Patents

COMPOSITIONS INCLUDING CANDIDA DUBLINIENSIS AND ALKALINIZED FUNGAL β-GLUCANS FOR PROTECTION AGAINST INFECTION-INDUCED SEPSIS Download PDF

Info

Publication number
WO2023240146A3
WO2023240146A3 PCT/US2023/068078 US2023068078W WO2023240146A3 WO 2023240146 A3 WO2023240146 A3 WO 2023240146A3 US 2023068078 W US2023068078 W US 2023068078W WO 2023240146 A3 WO2023240146 A3 WO 2023240146A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkalinized
fungal
glucans
protection against
induced sepsis
Prior art date
Application number
PCT/US2023/068078
Other languages
French (fr)
Other versions
WO2023240146A2 (en
Inventor
Mairi C. NOVERR
Amanda J. HARRIET
Original Assignee
The Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund filed Critical The Administrators Of The Tulane Educational Fund
Publication of WO2023240146A2 publication Critical patent/WO2023240146A2/en
Publication of WO2023240146A3 publication Critical patent/WO2023240146A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Materials Engineering (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present technology relates to methods for preventing or treating infection-induced sepsis (e.g., polymicrobial infection) in a subject in need thereof comprising administering to the subject an effective amount of an alkalinized fungal β-glucan extract or live wild-type Candida dubliniensis. Kits for use in practicing the methods are also provided.
PCT/US2023/068078 2022-06-08 2023-06-07 COMPOSITIONS INCLUDING CANDIDA DUBLINIENSIS AND ALKALINIZED FUNGAL β-GLUCANS FOR PROTECTION AGAINST INFECTION-INDUCED SEPSIS WO2023240146A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263350272P 2022-06-08 2022-06-08
US63/350,272 2022-06-08

Publications (2)

Publication Number Publication Date
WO2023240146A2 WO2023240146A2 (en) 2023-12-14
WO2023240146A3 true WO2023240146A3 (en) 2024-01-18

Family

ID=89119011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/068078 WO2023240146A2 (en) 2022-06-08 2023-06-07 COMPOSITIONS INCLUDING CANDIDA DUBLINIENSIS AND ALKALINIZED FUNGAL β-GLUCANS FOR PROTECTION AGAINST INFECTION-INDUCED SEPSIS

Country Status (1)

Country Link
WO (1) WO2023240146A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032170A1 (en) * 1992-08-21 2002-03-14 Spiros Jamas Underivatized, aqueous soluble beta (1-3) glucan, composition and method of making same
KR100700910B1 (en) * 2005-11-21 2007-03-28 고려대학교 산학협력단 Saccharomyces cerevisiae mutant producing alkali-soluble ?-glucan

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032170A1 (en) * 1992-08-21 2002-03-14 Spiros Jamas Underivatized, aqueous soluble beta (1-3) glucan, composition and method of making same
KR100700910B1 (en) * 2005-11-21 2007-03-28 고려대학교 산학협력단 Saccharomyces cerevisiae mutant producing alkali-soluble ?-glucan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE ET AL.: "Purification of soluble beta-glucan with immune-enhancing activity from the cell wall of yeast", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 65, no. 4, April 2001 (2001-04-01), pages 837 - 41, XP093006932, DOI: 10.1271/bbb.65.837 *

Also Published As

Publication number Publication date
WO2023240146A2 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
Kobayashi et al. Candiduria in hospital patients: a study prospective
CO4410317A1 (en) COMBINATION AND PHARMACEUTICAL SETS OF AN OPIOID ANTAGONIST AND A SELECTIVE RECEPTATION INHIBITOR OF SEROTONIN, AND THE TREATMENT OF ALCOHOLISM AND ALCOHOLIC DEPENDENCE USING THEM.
Irbe et al. Biodeterioration of external wooden structures of the Latvian cultural heritage
Eikenes et al. Comparison of chitosans with different molecular weights as possible wood preservatives
WO2003092629A3 (en) Methods of simultaneously treating mucositis and fungal infection
Highley Control of wood decay by Trichoderma (Gliocladium) virens I. Antagonistic properties
WO2023240146A3 (en) COMPOSITIONS INCLUDING CANDIDA DUBLINIENSIS AND ALKALINIZED FUNGAL β-GLUCANS FOR PROTECTION AGAINST INFECTION-INDUCED SEPSIS
CN104085013A (en) Aroma-enhancement flame-retardant modification treatment agent for wood floor timber
Yao et al. Role of gut-derived endotoxaemia and bacterial translocation in rats after thermal injury: effects of selective decontamination of the digestive tract
Petraitis et al. Combination therapy with isavuconazole and micafungin for treatment of experimental invasive pulmonary aspergillosis
Merinero et al. Do lichen secondary compounds play a role in highly specific fungal parasitism?
Kuka et al. Fungal degradation of wood plastic composites made with thermally modified wood residues
Hyakumachi et al. Role of melanin in susceptibility and resistance of Rhizoctonia solani to microbial lysis
Keča et al. Ecology of Armillaria species in managed forests and plantations in Serbia
WO2023055885A3 (en) Ezh2 inhibition in pancreatic cancer
WO2022192182A3 (en) USES OF GLUCOCORTICOID RECEPTOR (GR) ANTAGONIST, ANTIANDROGEN, AND AKT INHIBITOR/PI3K INHIBITOR/mTOR INHIBITOR COMBINATIONS
WO2007133749A3 (en) Methods and compositions for treating and preventing peripheral nerve damage
WO2020033723A4 (en) REGIMENS, COMPOSITIONS, AND METHODS OF TREATMENT WITH CAPSAICIN, TNFα INHIBITORS AND COMBINATIONS THEREOF
TWI718389B (en) Use of 3'-hydroxygenistein for anti-photoaging
D'hallewin et al. Citrus green mould control in stored'Star Ruby'grapefruit by the use of a bio-control yeast under curing conditions
Cookson Preservative treatments suitable for hardwood window joinery
US5518921A (en) Biological control for wood products and debarking
WO2020160493A3 (en) Compounds, compositions and methods for treatment of myopia
Lopes et al. Application of chitosan in the control of fungal infections by dermatophytes
CN107953433A (en) A kind of method of Calophyllum preservative treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23820621

Country of ref document: EP

Kind code of ref document: A2